BALTIMORE, Jan. 5, 2011 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has initiated research coverage of iBio, Inc. (NYSE Amex:IBIO), an emerging biotechnology company that has developed a unique alternative platform that could help revolutionize the mass production of key vaccines and biosimilars.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines the reasoning behind the coverage initiation.
"iBio's paradigm-changing platform takes the old model biotech and changes it such that revenue generation could be faster, along with lower capital costs. In our view, validation has already occurred with its relationships with and funding from DARPA and the Gates Foundation."
To view a summary of the report or download the report in its entirety, please visit
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap stock market research reports and weekly newsletters. For more information, visit .
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer. To download our research, disclosures, or for more information, visit .
About IBio, Inc.: iBio, Inc. (NYSE Amex:IBIO) a biotechnology company offering its proprietary, transformative iBioLaunch technology platform for the production of biologics including therapeutic proteins – orphan biologics, biosimilars and biobetters – and vaccines. The iBioLaunch platform uses transient gene expression in green plants for superior efficiency in protein production. The iBioLaunch technology was developed by the not-for-profit Fraunhofer USA Center for Molecular Biotechnology (FCMB) during the past eight years to overcome the inadequacies of existing technologies. iBio owns the intellectual property and technology developed at FCMB, and continues to sponsor development and application of the technology for biological applications in human health.
For more information and disclosures, visit .
CONTACT: Goldman Small Cap Research Rob Goldman, Analyst 410-609-7100 rob@goldmanresearch.com
